Evidence map›Paper›PMID 33269152›Full record

ArticleCureus2020

Immunotherapy Benefit in a Patient With Non-Small Cell Lung Cancer and a Rare BRAF Mutation.

Rebekah Rittberg, Shantanu Banerji, Susan Green, Gefei Qing, David E Dawe

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. [Strategic Exploration of Targeted Therapy for BRAF Non-V600E Mutant Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2022
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Rebekah RittbergOncology and Hematology, University of Manitoba, Winnipeg, CAN.
Shantanu BanerjiOncology and Hematology, CancerCare Manitoba, University of Manitoba, Winnipeg, CAN.
Susan GreenOncology and Hematology, CancerCare Manitoba, Winnipeg, CAN.
Gefei QingPathology, University of Manitoba, Winnipeg, CAN.
David E DaweOncology and Hematology, CancerCare Manitoba, University of Manitoba, Winnipeg, CAN.
Research Institute in Oncology and Hematology · CACancerCare Manitoba · CAUniversity of Manitoba · CAUniversity of Winnipeg · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy is less effective in non-small cell lung cancer (NSCLC) with driver mutations in epidermal growth factor receptor

Indexed as

brafdriver mutationimmune checkpoint inhibitornivolumabnon-small cell lung cancer

Identifiers

PMID33269152
PMCPMC7704186
OpenAlexW3096186999

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.